News
Zacks Investment Research on MSN1d
VALN Doses First Infant With Shigella Vaccine in Mid-Stage StudyShares of Valneva VALN rose 12% on Wednesday after the company announced that it has vaccinated the first participant in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback